Glenmark Pharma gets USFDA nod for two generic drugs
Glenmark has 62 ANDAs pending approvals from the US FDA and 106 products authorised for distribution in the US21-01-2016
21-01-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Glenmark Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.21-01-2016
Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated January 21, 2016 titled "Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg".21-01-2016
Glenmark Pharmaceuticals receives ANDA approval for Potassium Chloride Extended-Release Capsules USP, 10 mEq
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated January 21, 2016 titled "Glenmark Pharmaceuticals receives ANDA approval for Potassium Chloride Extended-Release Capsules USP, 10 mEq".21-01-2016
Q3 results on Jan 28, 2016
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 28, 2016 to consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2015 (Q3).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window closed for Directors and other designated employees of the Company on December 24,...18-01-2016
Investor Presentation
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of "Investor Presentation of the Company at J P Morgan Healthcare Conference in San Francisco, USA".12-01-2016
Glenmark starts studies on new drug aimed at cancer treatment
The novel clinical development candidate, GBR1342 is an antibody based on the company's proprietary BEAT platform.08-01-2016
Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel bi-specific monoclonal antibody targeting CD38
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated January 08, 2016 titled "Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel bi-specific monoclonal antibody targeting CD38".08-01-2016
Glenmark Pharma gains on tentative nod for Dronedarone tablets
The tablets are the generic version of Multaq tablets 400mg of Sanofi-Aventis U.s., LLC,06-01-2016
Glenmark Pharmaceuticals Inc., USA receives tentative ANDA approval for Dronedarone Tablets, 400 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated January 06, 2016, titled "Glenmark Pharmaceuticals Inc., USA receives tentative ANDA approval for Dronedarone Tablets, 400 mg".06-01-2016